Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $55.25 | Total: $276.25 |
| 1 | 10 | $46.80 | Total: $468.00 |
| 1 | 25 | $39.65 | Total: $991.25 |
| 1 | 50 | $33.80 | Total: $1,690.00 |
| 1 | 100 | $29.25 | Total: $2,925.00 |
Overview
Ridinilazole (SMT19969) is a novel narrow-spectrum nonabsorbable antibiotic. Ridinilazole showed potent inhibition of C. difficile (MIC90=0.125 mgL) and was markedly more active than either metronidazole (MIC90 = 8 mgL) or vancomycin (MIC90 = 2 mgL).
Chemical Properties
| Molecular Formula | C24H16N6 |
| Molecular Weight | 388.42 |
| CAS Numbers | 308362-25-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Vickers RJ, et al. Ridinilazole a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug;48[2] 137-43.